Liquid Biopsy Market New Innovations and Future Expansion by 2032Posted by Ganesh Shinde on February 24th, 2023 The global liquid biopsy market is anticipated to create lucrative growth opportunities over the projection period by exhibiting a total CAGR of 13.49% from 2022 to 2032. The global market is expected to be valued at US$ 1,146 Million in 2022 and surpass a valuation of around US$ 4,126 Million in 2032. The growth of the liquid biopsy market is attributed to increasing cancer incidences and low treatment rates. A liquid biopsy is known to be a non-invasive procedure as compared to surgical biopsies which aid in discovering a tumor with the help of a simple blood sample. Traces of cancer’s DNA in the blood can help in giving clues about which treatments are most likely to work for that patient. Liquid biopsies are commonly used to diagnose non-small cell lung cancer (NSCLC) and screening or a companion diagnostic for numerous other types of cancers such as gastrointestinal, colorectal, breast, prostate, and ovarian cancer. The Cost-effectiveness and high efficacy of liquid biopsy over several other diagnostic tests are chief factors responsible for market growth. Fast-track approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for non-invasive cancer diagnosis tests will continue creating growth opportunities. Key Companies:
Browse More@ https://www.futuremarketinsights.com/reports/liquid-biopsy-market Key Segments Profiled in the Liquid Biopsy Industry Survey Liquid Biopsy Market by Marker Type:
Liquid Biopsy Market by Sample Type:
Liquid Biopsy Market by Application Type:
Like it? Share it!More by this author |